Literature DB >> 15549146

CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients.

A Kosmaczewska, L Ciszak, K Suwalska, D Wolowiec, I Frydecka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15549146     DOI： 10.1038/sj.leu.2403588

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Authors:  Christopher J Ott; Alexander J Federation; Logan S Schwartz; Siddha Kasar; Josephine L Klitgaard; Romina Lenci; Qiyuan Li; Matthew Lawlor; Stacey M Fernandes; Amanda Souza; Donald Polaski; Deepti Gadi; Matthew L Freedman; Jennifer R Brown; James E Bradner
Journal:  Cancer Cell       Date:  2018-11-29       Impact factor: 31.743

Review 2.  The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors:  Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

3.  Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.

Authors:  Priscilla Do; Kyle A Beckwith; Carolyn Cheney; Minh Tran; Larry Beaver; Brittany G Griffin; Xiaokui Mo; Yang Liu; Rosa Lapalombella; Erin Hertlein; Natarajan Muthusamy; John C Byrd
Journal:  J Immunol       Date:  2019-03-25       Impact factor: 5.422

4.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Authors:  Andreas Herrmann; Saul J Priceman; Piotr Swiderski; Maciej Kujawski; Hong Xin; Gregory A Cherryholmes; Wang Zhang; Chunyan Zhang; Christoph Lahtz; Claudia Kowolik; Steve J Forman; Marcin Kortylewski; Hua Yu
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

5.  Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Authors:  Sara S Alhakeem; Mary K McKenna; Karine Z Oben; Sunil K Noothi; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Vivek M Rangnekar; Natarajan Muthusamy; Subbarao Bondada
Journal:  J Immunol       Date:  2018-04-30       Impact factor: 5.422

6.  Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.

Authors:  James W Smithy; Matthew J Pianko; Colleen Maher; Michael A Postow; Alexander N Shoushtari; Parisa Momtaz; Paul B Chapman; Jedd D Wolchok; Jae H Park; Margaret K Callahan
Journal:  J Immunother       Date:  2021-01       Impact factor: 4.912

7.  CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.

Authors:  Lidia Ciszak; Irena Frydecka; Dariusz Wolowiec; Aleksandra Szteblich; Agata Kosmaczewska
Journal:  Clin Exp Med       Date:  2015-05-24       Impact factor: 3.984

8.  BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

Authors:  Maissa Mhibik; Erika M Gaglione; David Eik; Ellen K Kendall; Amy Blackburn; Keyvan Keyvanfar; Maria Joao Baptista; Inhye E Ahn; Clare Sun; Junpeng Qi; Christoph Rader; Adrian Wiestner
Journal:  Blood       Date:  2021-11-11       Impact factor: 22.113

9.  Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Rae A Rohlfsen; Payal Gupta; Avadhut D Joshi; Ganapati V Hegde; R Gregory Bociek; Shantaram S Joshi
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

10.  Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.

Authors:  Lidia Ciszak; Irena Frydecka; Dariusz Wolowiec; Aleksandra Szteblich; Agata Kosmaczewska
Journal:  Tumour Biol       Date:  2015-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.